Compare HLF & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLF | TSHA |
|---|---|---|
| Founded | 1980 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | HLF | TSHA |
|---|---|---|
| Price | $17.07 | $4.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $16.00 | $10.56 |
| AVG Volume (30 Days) | 1.6M | ★ 2.8M |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.95 | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $4,961,900,000.00 | $6,310,000.00 |
| Revenue This Year | $1.12 | N/A |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | $5.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.04 | $1.05 |
| 52 Week High | $17.67 | $6.02 |
| Indicator | HLF | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 64.60 | 46.33 |
| Support Level | $16.40 | $4.48 |
| Resistance Level | $17.60 | $4.89 |
| Average True Range (ATR) | 0.68 | 0.28 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 61.84 | 40.90 |
Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management, targeted nutrition, Energy, Sports and Fitness, Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Latin America, EMEA, Asia Pacific regions, and China.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.